General Practitioners Advocate for Wegovy PBS Listing

A dedicated team of General Practitioners (GPs), led by Dr. Remon Eskandar, played a crucial role in advocating for the weight-loss medication semaglutide (marketed as Wegovy) to be subsidized under Australia's Pharmaceutical Benefits Scheme (PBS). Dr. Eskandar, a GP with extended skills in obesity management, emphasized the importance of treating obesity as a chronic and complex condition and ensuring affordable access to effective treatments.

The Challenge of Affordability

Wegovy, and similar medications, previously carried an annual cost of approximately $4500 or more, making it inaccessible for many patients. Monthly private script costs ranged from $400 to $800, creating a significant health equity divide.

GPs observed patients struggling with weight loss despite efforts in diet, exercise, and behavioral changes, highlighting the biological factors at play.

Strategic Advocacy: Focusing on Health Equity

Dr. Eskandar and a group of GPs developed a health equity statement and engaged with government officials, including the Health Minister's office and various state and national stakeholders. Their central message was clear:

"Obesity is a chronic disease, not a lifestyle choice, and access to treatment should not be a luxury."

They argued that investing in PBS listing would mitigate future costs associated with obesity-related conditions such as heart disease, diabetes, and obstructive sleep apnea.

Significant Progress: PBS Recommendation

Recognizing the substantial ongoing cost to the government, the advocacy focused on an initial target group: high-risk patients with severe obesity and pre-existing cardiovascular disease. Dr. Eskandar highlighted that data supports improved health outcomes and reduced healthcare costs for these patients by preventing cardiovascular complications and hospitalizations.

In late 2023, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended Wegovy's inclusion on the PBS for patients who have experienced a cardiovascular event. The Federal Health Minister confirmed ongoing discussions with Wegovy's manufacturer, Novo Nordisk, regarding the implementation steps. Dr. Eskandar views this as significant progress, removing financial barriers for eligible patients and enabling sustained weight loss and reduced cardiovascular risks.

The Path Forward: Expanding Access

Dr. Eskandar intends to continue advocating for PBS funding expansion for Wegovy and similar medications to include other conditions such as liver disease, renal issues, osteoarthritis, and obstructive sleep apnea.

He emphasized that GPs are uniquely positioned for advocacy due to their firsthand experience with the policy's impact on patients, allowing them to drive change through collective action and professional bodies.